Abstract:Objective: Restenosis is a common complication after endovascular treatment of peripheral artery disease. Drug-coated balloon (DCB) treatment has been proven safe and effective in reducing the rate of restenosis for simple and short lesions. However, the clinical results of DCBs for long lesions are still very limited. This study aimed to evaluate the efficacy and safety of DCBs in the treatment of long femoropopliteal artery disease. And the results of this study will also complement the existing evidence of DCB treatment of long lesions. Methods: Patients with lesion length >= 15cm according to computed tomography angiography (CTA) or angiography in the AcoArt I Study were included into this study. Based on the balloon catheter used in treatment, patients were divided into the DCB group and the percutaneous transluminal angioplasty (PTA) group. The demographic, lesion, and procedural characteristics and 24-month follow-up results were compared between the 2 groups. The primary efficacy endpoints were angiographic late lumen loss (LLL) at 6 months or at the time of clinically driven target lesion revascularization (CD-TLR), primary patency (PP), freedom from CD-TLR, and changes in the ankle-brachial index (ABI) and Rutherford class during 24 months of follow-up. The safety endpoint was the occurrence of major adverse events. Results: The total number of patients was 87, including 42 in the DCB group and 45 in the PTA group. There were no significant differences between the 2 groups in demographic, lesion, and procedural characteristics. The 6-month follow-up angiography showed that the LLL was significantly smaller in the DCB group than the PTA group (0.27 +/- 0.90 mm vs 1.32 +/- 0.91 mm; P < 0.001). At 24 months, compared with the PTA group, the DCB group had a significantly higher rate of freedom from CD-TLR (81.58% vs 43.18%; P < 0.001) and a significantly higher PP rate (46.88% vs 15.00%; P = 0.003). The DCB group had a significantly higher ABI than the PTA group at 6, 12, and 24 months (P < 0.001, P = 0.004 and P = 0.018, respectively). The DCB group had a better Rutherford class than the PTA group at 6 and 12 months (P = 0.033 and P = 0.012, respectively); the Rutherford class did not significantly differ between the 2 groups at 24 months (P = 0.127). The incidence of major adverse events did not significantly differ between the 2 groups. Conclusion: The effectiveness of the DCB is superior to a standard uncoated balloon in treating long lesions during 24 months of follow-up. Furthermore, the safety of the DCB is equivalent to that of PTA.

Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis

Paclitaxel Coated Balloon Versus Conventional Balloon Angioplasty in Dysfunctional Dialysis Arteriovenous Fistula: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Medium-term Result of Drug-Coated Balloon with Paclitaxel in Endovascular Treatment of Femoropopliteal Artery In- Stent Restenosis

A Randomized Comparison of Two Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis: the LONGTY ISR China Randomized Trial (LONGTY DCB Vs. SeQuent Please DCB).

Drug-Coated Balloon Angioplasty vs Plain Balloon Angioplasty in patients with coronary In-Stent Restenosis: A systematic review and meta-analysis of randomized controlled trials

Comparison of drug‐coated balloon angioplasty versus common balloon angioplasty for arteriovenous fistula stenosis: A systematic review and meta‐analysis

Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty For Coronary In-Stent Restenosis: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

Meta-Analysis Comparing Drug-Coated Balloon Versus Plain Old Balloon Angioplasty for In-stent Restenosis of Coronaries

Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.

A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial.

Drug‐coated Balloon for the Treatment of Small Vessel Disease: 9 Months of Angiographic Results and 12 Months of Clinical Outcomes of the PEPCAD China SVD Study

Short-term efficacy of paclitaxel -coated balloon in the treatment of femoropopliteal artery disease

Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study

Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial

Drug-Coated Balloon Angioplasty Compared with Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions (acoart II-BTK).

Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.

Comparison of Drug-Coated Balloons vs Bare-Metal Stents in Patients With Femoropopliteal Arterial Disease

LEA 35. Randomized, Multicenter Trial of ZENFlow Drug-Eluting Balloon in the Treatment of Femoropopliteal Artery Occlusive Disease

Comparison of safety and efficacy of femoropopliteal arterial disease using different dose drug-coated balloons: Systematic review and meta-analysis